NASDAQ$TARS
Tarsus Pharmaceuticals Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Reported strong fourth quarter and full-year 2024 financial results, with XDEMVY net product sales reaching $66.4 million for the quarter and $180.1 million for the year.
Tarsus Pharmaceuticals reported positive Q4 2024 financial results, highlighted by net product sales of XDEMVY reaching $66.4 million. The company continued to advance its pipeline, including TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention. Broad reimbursement coverage for XDEMVY was established, and a direct-to-consumer campaign was launched.
- Generated $66.4 million in XDEMVY net product sales during the fourth quarter of 2024.
- Dispensed more than 58,500 bottles of XDEMVY to patients in the fourth quarter of 2024.
- Expanded sales force contributed to increased ECP utilization and prescription volumes.
- Broad commercial, Medicare and Medicaid reimbursement of XDEMVY now extends to more than 90% of covered lives.
Headline financials
Revenue & EPS history
Tarsus · Revenue · Quarterly
$66.4M
Forward guidance
Tarsus is on track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027. In Japan, the Company expects to share results from a DB prevalence study in the first half of 2025, and meet with Japanese regulatory authorities to help determine a regulatory path forward. The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application (NDA) submitted by Tarsus’ partner, Grand Pharmaceutical Group Ltd., for TP-03 for DB.
Tailwinds
- Potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027.
- Initiated market development work, including Key Opinion Leader engagement, disease education and scientific presentations at major conferences.
- In Japan, the Company expects to share results from a DB prevalence study in the first half of 2025.
- The Chinese regulatory agency, National Medical Products Administration, accepted the New Drug Application (NDA) submitted by Tarsus’ partner, Grand Pharmaceutical Group Ltd., for TP-03 for DB.
- Planning to advance TP-05 for the potential prevention of Lyme disease.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+3.2%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+17.8%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+18.3%
Q2 2024
Best reaction
-10.5%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -8.4% | -9.0% | |
| Q4 2025 | +9.6% | +8.5% | -3.4% | |
| Q3 2025 | -4.7% | +1.8% | +14.4% | |
| Q1 2025 | -6.1% | -5.9% | -14.6% | |
| Q4 2024 | -9.3% | -2.3% | +11.2% | |
| Q3 2024 | -1.9% | -6.2% | +10.4% | |
| Q2 2024 | +18.3% | +16.5% | +34.8% | |
| Q1 2024 | -10.5% | +0.9% | -15.3% | |
| Q4 2023 | +14.2% | +11.4% | +9.6% | |
| Q3 2023 | +5.6% | +8.3% | +4.5% | |
| Q2 2023 | -2.5% | -1.5% | -7.0% | |
| Q1 2023 | +7.1% | +5.8% | +25.9% | |
| Q4 2022 | +0.4% | -10.6% | -15.8% | |
| Q3 2022 | -0.1% | -0.5% | -14.2% | |
| Q2 2022 | +5.4% | +0.6% | -8.3% | |
| Q1 2022 | +7.2% | +16.8% | +25.4% | |
| Q4 2021 | -4.9% | -4.7% | -1.1% | |
| Q3 2021 | +0.4% | -2.9% | -13.8% | |
| Q2 2021 | +6.2% | +3.7% | +13.3% | |
| Q1 2021 | +2.9% | +5.6% | +38.3% | |
| Q4 2020 | +16.4% | +15.8% | +8.6% | |
| Q1 2020 | +7.5% | +16.1% | +111.4% | |
| Q3 2020 | +7.5% | +16.1% | +111.4% | |
| Q2 2020 | +7.5% | +16.1% | +111.4% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro